Why are some of the new anti-Alzheimer’s antibodies better than others? With the FDA’s approval of Lecanemab and Donanemab, it’s worth staying on top of this topic’s latest research.
The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.
Kisunla, the newest Alzheimer’s drug, is rapidly gaining acceptance around the world. Learn what it does and how to get it.
How do the new drugs Leqembi and Kisunla fight Alzheimer’s? Surprisingly, increases in amyloid-beta protein levels can explain the slowing of Alzheimer’s at least as well as the reduction in amyloid plaques.
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.
Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide
In a new Alzheimer’s study, Rexulti (brexpiprazole) significantly reduced agitation. Learn the kinds of agitation it reduced and by how much.
There are no approved treatments for DLB, though it is the second most common type of dementia. Do drugs like donepezil hold the key?
While the initial headlines might seem discouraging, there’s always more to the story. 🌟
TRAILER: Robin Williams and his battle with Lewy Body Dementia.
There is a choice we make when a loved one gets Alzheimer’s. Walk away, or don’t walk away. Marilyn’s Mom told her to walk away. Marilyn chose not to. She’s glad she didn’t. Share her journey.
Anyone can give up,
It’s the easiest thing in the world to do.
But to hold it together
When everyone else would understand
If you fell apart,
That’s true strength.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
No spam, only news and updates.
